# Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

> **NCT00448864** · PHASE2 · TERMINATED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 75 (actual)

## Conditions studied

- Blood Loss, Surgical

## Interventions

- **DRUG:** Ecallantide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00448864
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05-01
- **Primary completion:** 2008-07-01
- **Final completion:** 2008-08-01
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** Experience gained from this study is sufficient to design and facilitate the follow-on study.
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448864, "Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00448864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*